Compare BX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BX | SNY |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1B | 95.7B |
| IPO Year | 2007 | 2001 |
| Metric | BX | SNY |
|---|---|---|
| Price | $119.48 | $48.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 11 |
| Target Price | ★ $138.86 | $54.92 |
| AVG Volume (30 Days) | ★ 4.9M | 4.5M |
| Earning Date | 10-22-2026 | 10-30-2026 |
| Dividend Yield | 4.00% | ★ 4.99% |
| EPS Growth | ★ 6.91 | N/A |
| EPS | ★ 3.19 | N/A |
| Revenue | ★ $14,450,265,000.00 | N/A |
| Revenue This Year | $4.12 | $3.68 |
| Revenue Next Year | $25.39 | $6.69 |
| P/E Ratio | $37.24 | ★ $6.14 |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $101.73 | $39.07 |
| 52 Week High | $165.14 | $52.67 |
| Indicator | BX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 76.60 |
| Support Level | $119.13 | $45.95 |
| Resistance Level | $120.34 | $48.78 |
| Average True Range (ATR) | 3.78 | 0.88 |
| MACD | 0.35 | 0.44 |
| Stochastic Oscillator | 29.18 | 92.43 |
Blackstone is the world's largest alternative-asset manager with $1.346 trillion in total assets under management, including $961.6 billion in fee-earning assets under management, at the end of June 2026. The company operates with scale in each of its major product lines: private equity (28% of fee-earning AUM and 35% of base management fees), real estate/real assets (29% and 32%), credit and insurance (33% and 25%), and other alternatives (10% and 8%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.